In 1977 she underwent, in the same site, melanoma (III Clarke's level) extirpation and local immunotherapy by DNCB ( dinitrochlorobenzene ).
Moshe Inbar et Al. ( Melanoma Research 1996/6/457-459 ) refers a case of melanoma, treated by DNCB in 1973, showing, the new skin, over the back, characterized by vitiligo like hypopigmentation and lack of hair.
The association vitiligo-melanoma has been known for several years.
S.Roul et Al. ( Nouv. Dermatol. 1996/15/574-578 ) analysed II cases coming to the conclusion that, althought the physiopathologic mechanism is unknown, it surely represents an immune reaction of the organism.
Ideed, an increasing number of antibodies against antigens of melanocytes and of melanoma malignant cells was observed (antigens 40-45 Kd / 79-90 Kd), and this is related to the extension of hypopigmented skin ( Cui and Bystrin, 1995 ).
Nevertheless, in rats with melanoma, exhibition of antibodies of vitiligo patients have been shown to prevent the development of lung metastates ( Fishman et Al. Cancer 1993/72/2365-2370 ).
Therefore, differently of vitiligo, vitiligo-like hypopigmentation observed after local immunotherapy, in course of melanoma, can be an inducted local immunoreaction capable to reduce local recidivism. (Abstract).
Prof. Camillo O. Di Cicco, MD. Presented at "The Seventh World Congress on Cancers of the Skin"
Catholic University of Rome, Italy.
- Personalized Cancer Therapy For Metastatic Melanoma- An Actual Breakthrough?
- 18% Fewer Deaths Since 2013: Melanoma Treatment Has Been A Huge Public Health Victory
- Protein Linked To Melanoma Recurrence
- Marker May Predict Response To Ipilimumab In Advanced Melanoma
- Study Of Patients With Melanoma Finds Most Have Few Moles